natgillin/translations-raw huggingface dataset:
A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/gas partition coefficient at 30 °C is 0.63 to 0.69).
Zaradi majhne topnosti sevoflurana v krvi (porazdelitveni koeficient med krvjo in plinom pri 30 °C je 0,63 do 0,69) se mora v krvi raztopiti minimalna količina sevoflurana, preden se alveolarni parcialni tlak uravnovesi z arterijskim parcialnim tlakom.
The concentration of sevoflurane necessary to maintain anaesthesia is much less than that required for induction.
Koncentracija sevoflurana, potrebna za vzdrževanje anestezije, je mnogo manjša od tiste, ki je potrebna za uvod v anestezijo.
Sevoflurane has a variable effect on heart rate, which tends to increase from baseline at low MAC and fall back with increasing MAC. Sevoflurane causes systemic vasodilation and produces dose dependent decreases in mean arterial pressure, total peripheral resistance, cardiac output and possibly the strength of myocardial contraction and speed of myocardial relaxation.
Sevofluran povzroča sistemsko vazodilatacijo in od odmerka odvisno zmanjšanje srednjega arterijskega tlaka, celotnega perifernega upora, minutnega volumna srca, lahko pa tudi jakosti kontrakcij srčne mišice in hitrosti relaksacije srčne mišice.
• Use a cuffed endotracheal tube when possible for the administration of Sevohale during maintenance anaesthesia.
• Kadar je možno, uporabljajte za dajanje Sevohalea med vzdrževalno anestezijo endotrahealni tubus z mešičkom.
PACKAGE LEAFLET: Sevohale Inhalation vapour, liquid for dogs and cats, 100% v/v sevoflurane
NAVODILO ZA UPORABO Sevohale Para za inhaliranje, tekočina za pse in mačke, 100 % v/v sevofluran.
Sevoflurane administration adversely affects the autoregulation of renal blood flow in dogs and cats.
Uporaba Sevoflurana neugodno vpliva na avtoregulacijo pretoka krvi skozi ledvice pri psih.
which are typically 1.3 to 1.5 times the MAC value.
Mnogokratniki MAC se uporabljajo kot smernica za kirurške ravni anestezije, ki so tipično 1,3 do 1,5-kratnik vrednosti MAC.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena..
However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches and queens undergoing caesarean section, without any ill effects being detected in either the bitch or queen, or the puppies or kittens.
Vendar so z uporabo sevoflurana po uvodu v anestezijo s propofolom pri psicah in mačkah po carskem rezu na voljo omejene klinične izkušnje, pri tem niso odkrili nikakršnih škodljivih učinkov niti pri psici in mački niti pri kužkih ali mačjih mladičih.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC ODGOVOREN ZA SPROSTITEV SERIJE
Inhalation vapour, liquid.
Para za inhaliranje, tekočina.
During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose dependent decrease in blood pressure.
Med vzdrževanjem anestezije povzroči zviševanje koncentracije sevoflurana od odmerka odvisno znižanje krvnega tlaka.
In the absence of premedication, inhaled concentrations of sevoflurane in the range of 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.
Če premedikacije ni, bodo inhalirane koncentracije sevoflurana v mejah 3,7 do 3,8 % pri zdravem psu povzročile kirurške ravni anestezije.
For operator warnings - read the package leaflet before use.
Pred uporabo preberite navodilo za uporabo, kjer boste našli opozorila za kirurga.
In common with other inhalational anaesthetics, the minimum alveolar concentration (MAC) of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids.
Tako kot pri drugih inhalacijskih anestetikih sočasna uporaba benzodiazepinov in opioidov zmanjša minimalno alveolarno koncentracijo (MAC) sevoflurana.
The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs and cats cannot be ruled out.
Ni mogoče izključiti možnosti, da bi sevofluran pri dovzetnih psih in mačkah sprožil epizode maligne hipertermije.
In order to minimise exposure to sevoflurane vapour, the following recommendations are made:
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Da bi kar najbolj zmanjšali izpostavitev hlapom sevoflurana, priporočamo naslednje:
In cats, transient increases in AST and ALT may occur with sevoflurane, however, hepatic enzymes tend to remain within the normal range.
Pri mačkah se lahko pri sevofluranu pojavi prehodno zvišanje aspartatne aminotransferaze (AST), alaninske aminotransferaze (ALT), medtem, ko jetrni encimi ostanejo v normalnem območju
Long duration, low-flow sevoflurane anaesthesia should be avoided due to the risks of Compound A accumulation.
Zaradi nevarnosti kopičenja spojine A se je treba dolgotrajni nizkopretočni sevofluranski anesteziji izogibati.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton box
PODATKI NA STIČNI OZ. PRIMARNI OVOJNINI Nalepka za steklenice
Neuromuscular blocking agents have been used in cats anaesthetised with sevoflurane without any unexpected effects
Neuromuskularni blokatorji so bili uporabljeni pri mačkah,
benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Anestezijske sheme, ki vključujejo premedikacijo z opioidi, alfa-2-agonisti, benzodiazepini ali fenotiazini, dopuščajo uporabo nižjih vzdrževalnih koncentracij sevoflurana.
IRELAND
IRSKA.
Teл: +353 91 841788
IE - Ireland Teл: +353 91 841788
This means that there is more evidence to come about the vaccine, which the company is required to provide.
To pomeni, da se pričakujejo dodatni dokazi o cepivu, ki jih mora zagotoviti podjetje.
Further information on Ervebo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Ervebo.
Dodatne informacije o zdravilu Ervebo so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Ervebo.
What measures are being taken to ensure the safe and effective use of Ervebo?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ervebo?
Ervebo can only be obtained with a prescription and should be used in accordance with official recommendations.
Zdravilo Ervebo se izdaja le na recept in ga je treba uporabljati v skladu z uradnimi priporočili.
The European Medicines Agency therefore decided that Ervebo's benefits are greater than its risks and that it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Ervebo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
People received a single dose of Ervebo either immediately or after 21 days.
Osebe so prejele enkratni odmerek zdravila Ervebo takoj ali po 21 dneh.
Since Ervebo has been given conditional authorisation, the company that markets Ervebo will provide additional details on certain aspects of the production process.
Ker je zdravilo Ervebo dobilo pogojno dovoljenje, bo podjetje, ki ga trži, zagotovilo dodatne podrobnosti o nekaterih vidikih proizvodnega procesa.
Ervebo is given by a trained healthcare worker.
Zdravilo Ervebo daje usposobljen zdravstveni delavec.
As for all medicines, data on the use of Ervebo are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Ervebo stalno spremljajo.
The most common side effects with Ervebo (which may affect more than 1 in 10 people) are pain, swelling and redness at the injection site, headache, fever, muscle pain, tiredness and joint pain.
Najpogostejši neželeni učinki zdravila Ervebo (ki se lahko pojavijo pri več kot 1 od 10 oseb) so bolečina, oteklina in pordelost na mestu injiciranja, glavobol, zvišana telesna temperatura, bolečine v mišicah, utrujenost in bolečine v sklepih.
Amongst the 2,108 people who received immediate vaccination, none had Ebola virus disease between 10 days and 31 days after vaccination; amongst those whose vaccination was delayed (1429 people), 10 developed the disease within 31 days after vaccination.
Pri 2 108 osebah, ki so bile cepljene takoj, se v 10 do 31 dneh po cepljenju bolezen ebola ni pojavila; pri tistih, ki so bile cepljene pozneje (1 429 oseb), pa se je bolezen v 31 dneh po cepljenju razvila pri 10 osebah.
Other information about Ervebo
Druge informacije o zdravilu Ervebo
What are the risks associated with Ervebo?
Kakšna tveganja so povezana z zdravilom Ervebo?
The vesicular stomatitis virus itself has little or no effect on humans.
Virus vezikularnega stomatitisa ne vpliva ali le malo vpliva na ljudi.
The effectiveness of the vaccine to protect against confirmed Ebola virus disease was measured by comparing the number of cases occurring 10 to 31 days after vaccination in the group of people vaccinated immediately, versus the number of cases in the group of people who were vaccinated later.
Učinkovitost cepiva pri zaščiti pred potrjeno boleznijo ebola je bila izmerjena na podlagi primerjave števila primerov pojava bolezni v 10 do 31 dneh po cepljenju v skupini oseb, ki so bili cepljene takoj, in števila primerov bolezni v skupini oseb, ki so bile cepljene pozneje.
Ervebo must not be used in people who are hypersensitive (allergic) to rice or to any ingredients of the vaccines.
Zdravilo Ervebo se ne sme uporabljati pri osebah, ki so preobčutljive (alergične) na riž ali katero koli drugo sestavino cepiva.
Why is Ervebo authorised in the EU?
Zakaj je bilo zdravilo Ervebo odobreno v EU?
What benefits of Ervebo have been shown in studies?
Kakšne koristi zdravila Ervebo so se pokazale v študijah?
An overview of Ervebo and why it is authorised in the EU
Pregled zdravila Ervebo in zakaj je odobreno v EU
Ervebo has been given ‘conditional authorisation'.
Zdravilo Ervebo je pridobilo „pogojno dovoljenje za promet“.
The vaccine only contains one protein from Zaire Ebola virus and cannot cause the disease.
Cepivo vsebuje samo eno beljakovino iz virusa Ebola Zaire in ne more povzročiti bolezni.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ervebo have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ervebo upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Ervebo is effective in protecting adults from Ebola virus disease; however, the duration of this protection is currently unknown.
Zdravilo Ervebo je učinkovito pri zaščiti odraslih pred boleznijo ebola, vendar trajanje te zaščite trenutno ni znano.
What is Ervebo and what is it used for?
Kaj je zdravilo Ervebo in za kaj se uporablja?
Side effects with Ervebo were similar to those of most vaccines; they were mild to moderate in intensity and generally lasted less than a week.
Neželeni učinki zdravila Ervebo so podobni kot pri večini cepiv; so blagi do zmerno intenzivni in običajno trajajo manj kot teden dni.
For more information about using Ervebo, see the package leaflet or contact your doctor or pharmacist.
Dodatne informacije o uporabi zdravila Ervebo si oglejte v navodilu za uporabo ali pa se posvetujte z zdravnikom ali farmacevtom.
In general, these reactions occur within 7 days after vaccination, were mild to moderate in intensity and resolved in less than a week.
Običajno se te reakcije pojavijo v 7 dneh po cepljenju, so blage in izzvenijo v manj kot tednu dni.
It is given as a single 1 ml injection into the muscle around the shoulder (the deltoid) or a muscle of the thigh.
Cepivo se injicira v enkratnem 1-mililitrskem odmerku v ramensko (deltoidno) ali stegensko mišico.
When a person receives the vaccine, it triggers an immune response against the virus protein.
Ko oseba prejme cepivo, to povzroči imunski odziv na beljakovino virusa.
Later, when the person comes into contact with the actual virus, the immune system recognises the virus protein and is already prepared to attack the virus and so protects the person from Ebola virus disease.
Ko oseba pozneje pride v stik z dejanskim virusom, imunski sistem prepozna beljakovino virusa in je že pripravljen za napad na virus, tako da zaščiti osebo pred ebolo.
What information is still awaited for Ervebo?
Katere informacije o zdravilu Ervebo še pričakujemo?
Side effects reported with Ervebo are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Ervebo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
A main study showed that Ervebo was effective in preventing Ebola virus disease in adults at risk of infection during an outbreak.
Glavna študija je pokazala, da je zdravilo Ervebo učinkovito preprečevalo ebolo pri odraslih, pri katerih obstaja tveganje okužbe med izbruhom bolezni.
The study was conducted in Guinea during an Ebola outbreak and involved people who were either direct contacts or contacts of contacts of someone who had Ebola virus disease.
Študija je bila izvedena v Gvineji med izbruhom ebole in je zajela osebe, ki so bile bodisi v neposrednem stiku z obolelim za ebolo bodisi v stiku z osebami, ki so bile v stiku z obolelimi.
Healthcare workers and other carers who have been vaccinated with Ervebo should also continue to apply standard precautions for safe injection and hygiene and wear personal protective equipment when caring for patients with known or suspected Ebola virus disease.
Zdravstveni delavci in drugo negovalno osebje, ki so bili cepljeni s cepivom Ervebo, bi morali pri oskrbi bolnikov, za katere je znano, da imajo ebolo, ali pri katerih obstaja sum nanjo, še naprej uporabljati običajne previdnostne ukrepe za varno injiciranje in higieno ter opremo za osebno zaščito.
Ervebo is a vaccine to protect adults aged 18 years and older against Ebola virus disease caused by the Zaire Ebola virus.
Zdravilo Ervebo je cepivo za zaščito odraslih, starih 18 let in več, pred ebolo, ki jo povzroča virus Ebola Zaire.
People vaccinated with Ervebo should continue to take precautions to protect themselves from Ebola virus disease.
Osebe, ki so bile cepljene s cepivom Ervebo, bi morale še naprej izvajati previdnostne ukrepe, da se zaščitijo pred ebolo.
Ervebo contains a virus known as vesicular stomatitis virus which has been weakened and modified to contain a protein from the Zaire Ebola virus.
Zdravilo Ervebo vsebuje virus vezikularnega stomatitisa, ki je bil oslabljen in spremenjen tako, da vsebuje beljakovino iz virusa Ebola Zaire.
Ervebo should be used in individuals at risk of infection with Ebola virus.
Zdravilo Ervebo je treba dajati osebam, pri katerih obstaja nevarnost okužbe z virusom ebole.
How is Ervebo used?
Kako se zdravilo Ervebo uporablja?
How does Ervebo work?
Kako deluje zdravilo Ervebo?
For the full list of side effects and restrictions of Ervebo, see the package leaflet.
Celotni seznam neželenih učinkov in omejitev pri uporabi zdravila Ervebo je na voljo v navodilu za uporabo.
The active substance in Ervebo contains a protein found on the Ebola Zaire virus.
Učinkovina v zdravilu Ervebo vsebuje beljakovino virusa Ebola Zaire.
This helps to protect against the disease.
To pomaga pri zaščiti pred boleznijo.
Every year, the European Medicines Agency (EMEA) will review any new information that may become available and this summary will be updated as necessary.
Evropska agencija za zdravila (EMEA) bo vsako leto pregledala nove informacije, ki bodo morda postale razpoložljive, in po potrebi posodobila ta povzetek.
These usually disappear within one to two days without treatment.
Ti neželeni učinki običajno minejo brez zdravljenja v 1-2 dneh.
It contains a flu strain called A/Viet Nam/1194/2004 (H5N1).
Vsebuje sev gripe, imenovan A/Viet Nam/1194/2004 (H5N1).
They will then collect information on the safety and effectiveness of the final pandemic vaccine, and submit this to the CHMP for evaluation.
Tedaj bodo zbrali informacije o varnosti in učinkovitosti končnega pandemičnega cepiva in jih posredovali v oceno CHMP.
The vaccine also contains an ‘adjuvant' (a compound containing aluminium) to stimulate a better response.
Cepivo vsebuje tudi „adjuvans“ (spojino, ki vsebuje aluminij) za stimulacijo boljšega odziva.
This will include information on its side effects and its safety in children, pregnant women, patients with severe conditions, and people who have problems with their immune systems.
Te informacije bodo vključevale podatke o njegovih neželenih učinkih ter njegovi varnosti pri otrocih, nosečnicah, resno bolnih bolnikih in ljudeh, ki imajo težave z imunskim sistemom.
It is given by injection into the upper arm muscle.
Daje se z injekcijo v mišico nadlakti.
This is a special type of vaccine that can be developed to help with the management of a pandemic.
To je posebna vrsta cepiva, ki ga je mogoče razviti za pomoč pri nadzorovanju pandemije.
The virus is whole, but it has been inactivated (killed) so that it does not cause disease.
Virus je cel, vendar inaktiviran (ubit), tako da ne povzroča bolezni.
The European Commission granted a marketing authorisation valid throughout the EU for Daronrix to GlaxoSmithKline Biologicals s.a. on 21 March 2007.
Evropska komisija je dovoljenje za promet z zdravilom Daronrix, veljavno po vsej Evropski uniji, odobrila družbi GlaxoSmithKline Biologicals s.a. dne 21. marca 2007.
The main measures of effectiveness were the levels of antibodies against the flu virus in the patients' blood before vaccination, on the day of the second injection (day 21), and 21 days later (day 42).
Glavna merila učinkovitosti so bile koncentracije protiteles proti virusu gripe v krvi bolnika pred cepljenjem, na dan drugega cepljenja (21. dan) in 21 dni kasneje (na 42. dan).
This means that because the strain of flu virus that may cause a pandemic is not known, it has not been possible to obtain full information about the future pandemic vaccine.
To pomeni, da zaradi tega, ker sev virusa, ki utegne povzročiti pandemijo, ni znan, ni bilo mogoče pridobiti celovitih informacij o cepivu za bodočo pandemijo.
They can test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing a pandemic is included.
To cepivo lahko preizkusijo, da bi preverili, kako se ljudje nanj odzivajo, na podlagi česar lahko predvidevajo, kako se bodo ljudje odzivali, ko se bo pojavil sev gripe, ki povzroča pandemijo.
21 days after the second injection, 70.8% of the people receiving the vaccine had levels of antibodies that would protect them against H5N1.
Enaindvajset dni po drugem injiciranju je imelo 70,8 % ljudi, ki so prejeli cepivo, koncentracijo protiteles, ki bi jih lahko zaščitila proti H5N1.
Daronrix contains small amounts of a virus called H5N1.
Zdravilo Daronrix vsebuje majhne količine virusa, imenovanega H5N1.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Cepiva delujejo tako, da imunski sistem (naravno obrambo telesa) »naučijo«, kako naj se brani pred boleznijo.
The effects of Daronrix were first tested in experimental models before being studied in humans.
Učinki zdravila Daronrix so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
This summary was last updated in 03-2007.©EMEA 2007
Ta povzetek je bil nazadnje posodobljen 03-2007.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) DARONRIX EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) DARONRIX Povzetek EPAR za javnost
Daronrix is given in two doses, at least three weeks apart.
Zdravilo Daronrix se daje v dveh odmerkih v razmaku najmanj treh tednov.
Daronrix has been authorised under “Exceptional Circumstances”.
Zdravilo Daronrix je bilo odobreno v »izjemnih okoliščinah«.
Daronrix is a vaccine that can only be used once a flu ‘pandemic' has been officially declared by the World Health Organization (WHO) or European Union (EU).
Zdravilo Daronix je cepivo, ki se lahko uporablja šele potem, ko Svetovna zdravstvena organizacija (WHO) ali Evropska unija (EU) uradno razglasi pandemijo gripe.
According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable.
V skladu z merili, ki jih je določil Odbor za zdravila za uporabo v humani medicini (CHMP), morajo modelna cepiva, da lahko veljajo kot primerna, zagotoviti zaščitno koncentracijo protiteles pri vsaj 70 % ljudi.
Before a pandemic starts, nobody knows which strain of flu virus will be involved, so companies cannot prepare the correct vaccine in advance.
Pred začetkom pandemije ni znano, kateri sev virusa gripe bo razsajal, zato podjetja ne morejo vnaprej pripraviti pravega cepiva.
It is a suspension for injection that contains influenza (flu) viruses that have been inactivated (killed).
Je suspenzija za injiciranje, ki vsebuje inaktivirane (ubite) viruse gripe.
Daronrix should not be given to patients who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any substances found at trace levels in the vaccine, such as eggs, chicken protein or gentamicin sulphate (an antibiotic).
Zdravila Daronrix se ne sme dajati bolnikom, ki so imeli v preteklosti anafilaktično reakcijo (hudo alergijsko reakcijo) na katero koli izmed sestavin cepiva ali na katero koli od snovi, ki se v sledeh nahajajo v cepivu, kot npr. na jajca, piščančje beljakovine ali gentamicinijev sulfat (antibiotik).
If a pandemic has started, however, it may be appropriate to give the vaccine to these patients, as long as facilities for resuscitation are available.
Vendar pa bo v pandemičnih razmerah cepljenje takih bolnikov morda vseeno upravičeno, če bo na voljo oprema za oživljanje.
Instead, they can prepare a vaccine that contains a strain of flu virus specifically chosen because nobody has been exposed to it, and to which nobody is immune.
Lahko pa pripravijo cepivo, ki vsebuje posebej izbran sev virusa gripe, ki mu ni bil še nihče izpostavljen in na katerega ni nihče imun.
Other information about Daronrix:
Druge informacije o zdravilu Daronrix:
Daronrix would be given according to official recommendations.
Zdravilo Daronrix se daje v skladu z uradnimi priporočili.
Which measures are being taken to ensure the safe use of Daronrix?
Kateri ukrepi se izvajajo za zagotavljanje varne uporabe zdravila Daronrix?
When a person is given the vaccine, the immune system recognises the inactivated virus as ‘foreign' and makes antibodies against it.
Ko oseba prejme cepivo, imunski sistem prepozna inaktiviran virus kot tujek in proti njemu razvije protitelesa.
The committee recommended that Daronrix be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Daronrix podeli dovoljenje za promet.
The study showed that Daronrix containing 15 micrograms of haemagglutinin and the adjuvant produced an antibody response that satisfies these criteria.
Raziskava je pokazala, da zdravilo Daronrix, vsebujoče 15 mikrogramov hemaglutinina in adjuvans, izzove odziv protiteles, ki zadovolji to merilo.
If Daronrix is used during a pandemic, the company that makes it will collect information on the safety of the vaccine while it is being used.
Če se bo zdravilo Daronrix uporabljalo med pandemijo, bo podjetje, ki ga izdeluje, zbralo informacije o varnosti cepiva med njegovo uporabo.
The CHMP concluded that Daronrix's benefits outweighed its risks, and that it had shown its suitability as a mock-up vaccine in preparation for a pandemic flu outbreak.
CHMP je zaključil, da prednosti zdravila Daronrix presegajo z njim povezana tveganja ter da se je zdravilo izkazalo kot ustrezno za modelno cepivo za primer izbruha pandemične gripe.
The most common side effects with Daronrix (seen in more than 1 in 10 people) are headache, pain and redness at the site of the injection, and fatigue (tiredness).
Najpogostejši neželeni učinki zdravila Daronrix (opaženi pri več kot 1 bolniku izmed 10) so glavobol, bolečina in rdečina na mestu injiciranja ter utrujenost.